Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice.

Annals of neurology - 1 Apr 2015

Zhou Qiong, Wang Man, Du Ying, Zhang Wei, Bai Miao, Zhang Zhuo, Li Zhuyi, Miao Jianting

Abstract excerpt

OBJECTIVE: Growing evidence indicates that the activation of c-Jun N-terminal kinase (JNK) is implicated in the multiple major pathological features of Alzheimer disease (AD). However, whether specific inhibition of JNK activation could prevent disease progression in adult transgenic AD models at moderate stage remains unknown. Here we first investigated the potential disease-modifying therapeutic effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Protein Precursor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anthracenes

Share to JNK Mitogen-Activated Protein Kinases

Share to Mice, Transgenic

Share to Phenotype

Share to Presenilin-1

Source

Identifiers

PMID: 25611954
DOI: 10.1002/ana.24361

Genes

APP
ADAM10
BACE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice.PMID 25611954Read ↗

The Loss of c-Jun N-Terminal Protein Kinase Activity Prevents the Amyloidogenic Cleavage of Amyloid Precursor Protein and the Formation of Amyloid Plaques<i>In Vivo</i>Semantic proximity Read ↗

c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s DiseasesSemantic proximity Read ↗

JNK regulates APP cleavage and degradation in a model of Alzheimer's disease.Semantic proximity Read ↗

Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in <scp>A</scp>lzheimer's disease transgenic miceSemantic proximity Read ↗

Curcumin Shows Neuroprotection against Oxidative Damage and Alters APP Processing Involving GSK-3β-mediated Protein O-GlcNAcylationSemantic proximity Read ↗

MiR-335-5p Inhibits β-Amyloid (Aβ) Accumulation to Attenuate Cognitive Deficits Through Targeting c-jun-N-terminal Kinase 3 in Alzheimer’s DiseaseSemantic proximity Read ↗

A Novel Inhibitor Targeting NLRP3 Inflammasome Reduces Neuropathology and Improves Cognitive Function in Alzheimer’s Disease Transgenic MiceSemantic proximity Read ↗

Activation of JNK signaling mediates amyloid-ß-dependent cell death.Semantic proximity Read ↗

Amyloid-β₄₂ activates the expression of BACE1 through the JNK pathway.Semantic proximity Read ↗

β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models.Semantic proximity Read ↗

Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw.Semantic proximity Read ↗

Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.